Dupilumab-induced psoriasiform dermatitis in two pediatric cardiac transplant patients

Trevor Lockard; Sarah A. Mullen; Erica B. Lee; Hana Niebur; Nicole Harter

doi:10.1111/pde.15497

Dupilumab-induced psoriasiform dermatitis in two pediatric cardiac transplant patients

Trevor Lockard, Sarah A. Mullen, Erica B. Lee, Hana Niebur, Nicole Harter

Research output: Contribution to journal › Article › peer-review

2 Scopus citations

Abstract

Dupilumab is an interleukin-4 receptor antagonist important in the treatment of refractory atopic dermatitis (AD), particularly among pediatric patients. Two boys with a history of AD and cardiac transplant who developed psoriasiform dermatitis in response to dupilumab therapy are reported. These patients paradoxically developed an immune-mediated adverse drug reaction despite taking systemic immunosuppressive agents. While the literature suggests possible pathomechanisms for psoriasiform dermatitis despite immunosuppression, further research is necessary to better characterize this unique and unexpected phenomenon.

Original language	English (US)
Pages (from-to)	508-511
Number of pages	4
Journal	Pediatric dermatology
Volume	41
Issue number	3
DOIs	https://doi.org/10.1111/pde.15497
State	Published - May 1 2024

Keywords

dermatologic agents
drug eruptions
eczema
pediatrics
transplant recipients

ASJC Scopus subject areas

Pediatrics, Perinatology, and Child Health
Dermatology

Access to Document

10.1111/pde.15497

Cite this

@article{10c1d20882014003b9d48642172036cf,

title = "Dupilumab-induced psoriasiform dermatitis in two pediatric cardiac transplant patients",

abstract = "Dupilumab is an interleukin-4 receptor antagonist important in the treatment of refractory atopic dermatitis (AD), particularly among pediatric patients. Two boys with a history of AD and cardiac transplant who developed psoriasiform dermatitis in response to dupilumab therapy are reported. These patients paradoxically developed an immune-mediated adverse drug reaction despite taking systemic immunosuppressive agents. While the literature suggests possible pathomechanisms for psoriasiform dermatitis despite immunosuppression, further research is necessary to better characterize this unique and unexpected phenomenon.",

keywords = "dermatologic agents, drug eruptions, eczema, pediatrics, transplant recipients",

author = "Trevor Lockard and Mullen, {Sarah A.} and Lee, {Erica B.} and Hana Niebur and Nicole Harter",

note = "Publisher Copyright: {\textcopyright} 2023 The Authors. Pediatric Dermatology published by Wiley Periodicals LLC.",

year = "2024",

month = may,

day = "1",

doi = "10.1111/pde.15497",

language = "English (US)",

volume = "41",

pages = "508--511",

journal = "Pediatric dermatology",

issn = "0736-8046",

publisher = "John Wiley and Sons Inc.",

number = "3",

}

TY - JOUR

T1 - Dupilumab-induced psoriasiform dermatitis in two pediatric cardiac transplant patients

AU - Lockard, Trevor

AU - Mullen, Sarah A.

AU - Lee, Erica B.

AU - Niebur, Hana

AU - Harter, Nicole

PY - 2024/5/1

Y1 - 2024/5/1

N2 - Dupilumab is an interleukin-4 receptor antagonist important in the treatment of refractory atopic dermatitis (AD), particularly among pediatric patients. Two boys with a history of AD and cardiac transplant who developed psoriasiform dermatitis in response to dupilumab therapy are reported. These patients paradoxically developed an immune-mediated adverse drug reaction despite taking systemic immunosuppressive agents. While the literature suggests possible pathomechanisms for psoriasiform dermatitis despite immunosuppression, further research is necessary to better characterize this unique and unexpected phenomenon.

AB - Dupilumab is an interleukin-4 receptor antagonist important in the treatment of refractory atopic dermatitis (AD), particularly among pediatric patients. Two boys with a history of AD and cardiac transplant who developed psoriasiform dermatitis in response to dupilumab therapy are reported. These patients paradoxically developed an immune-mediated adverse drug reaction despite taking systemic immunosuppressive agents. While the literature suggests possible pathomechanisms for psoriasiform dermatitis despite immunosuppression, further research is necessary to better characterize this unique and unexpected phenomenon.

KW - dermatologic agents

KW - drug eruptions

KW - eczema

KW - pediatrics

KW - transplant recipients

UR - http://www.scopus.com/inward/record.url?scp=85179741223&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85179741223&partnerID=8YFLogxK

U2 - 10.1111/pde.15497

DO - 10.1111/pde.15497

M3 - Article

C2 - 38097389

AN - SCOPUS:85179741223

SN - 0736-8046

VL - 41

SP - 508

EP - 511

JO - Pediatric dermatology

JF - Pediatric dermatology

IS - 3

ER -

Dupilumab-induced psoriasiform dermatitis in two pediatric cardiac transplant patients

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this